TWD 38.95
(2.5%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 1.46 Billion TWD | 168.68% |
2022 | 545.18 Million TWD | -10.36% |
2021 | 608.22 Million TWD | 26.49% |
2020 | 480.85 Million TWD | -3.17% |
2019 | 496.6 Million TWD | -62.81% |
2018 | 1.33 Billion TWD | 9.33% |
2017 | 1.22 Billion TWD | -29.27% |
2016 | 1.72 Billion TWD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 2.11 Billion TWD | 44.58% |
2024 Q1 | 1.46 Billion TWD | -0.29% |
2023 Q4 | 1.46 Billion TWD | 27.21% |
2023 FY | 1.46 Billion TWD | 168.68% |
2023 Q3 | 1.15 Billion TWD | 2.1% |
2023 Q2 | 1.12 Billion TWD | 0.3% |
2023 Q1 | 1.12 Billion TWD | 106.24% |
2022 Q2 | 591.05 Million TWD | -33.26% |
2022 Q1 | 885.65 Million TWD | 0.0% |
2022 Q3 | 610.89 Million TWD | 3.36% |
2022 Q4 | 545.18 Million TWD | -10.76% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Apex Biotechnology Corp. | 500.07 Million TWD | -192.916% |
Sinphar Pharmaceutical Co.,Ltd. | 2.85 Billion TWD | 48.662% |
Panion & Bf Biotech Inc. | 1.32 Billion TWD | -10.625% |
Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 1.82 Billion TWD | 19.58% |
GenMont Biotech Incorporation | 204.05 Million TWD | -617.824% |
Abnova (Taiwan) Corporation | 69.42 Million TWD | -2009.91% |
Adimmune Corporation | 3.7 Billion TWD | 60.485% |
Tanvex BioPharma, Inc. | 1.94 Billion TWD | 24.585% |
Energenesis Biomedical CO.,LTD. | 24.58 Million TWD | -5857.555% |
UnicoCell Biomed Co., Ltd. | 89.48 Million TWD | -1536.868% |
PELL Bio-Med Technology Co. Ltd. | 236.76 Million TWD | -518.666% |